Ask AI
NSCLC Treatment Paradigm
Expert View on the Evolving Treatment Paradigm in Advanced NSCLC

Released: June 23, 2020

Activity

Progress
1
Course Completed

In this module, Matthew Gubens, MD, MS, provides an overview of the current status of advanced non-small-cell lung cancer (NSCLC) management, including recent advances in targeted agents, and immune checkpoint inhibitors.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with advanced NSCLC do you typically provide care for in a month?
What is the most appropriate initial therapy?
In your current practice, which of the following treatment options would you recommend for this patient?
How would you choose to initially manage his diarrhea?